Jean Mulcahy Levy
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proto-Oncogene Proteins B-raf | 6 | 2021 | 204 | 2.550 |
Why?
| Autophagy | 8 | 2021 | 321 | 2.350 |
Why?
| Brain Neoplasms | 10 | 2021 | 1016 | 2.020 |
Why?
| Glioma | 6 | 2021 | 300 | 1.720 |
Why?
| Central Nervous System Neoplasms | 3 | 2019 | 129 | 1.650 |
Why?
| Chloroquine | 3 | 2017 | 63 | 0.720 |
Why?
| Transplantation, Autologous | 1 | 2019 | 189 | 0.650 |
Why?
| Chordoma | 1 | 2017 | 13 | 0.610 |
Why?
| Skull Base Neoplasms | 1 | 2017 | 27 | 0.600 |
Why?
| Indoles | 2 | 2017 | 318 | 0.600 |
Why?
| Tuberous Sclerosis | 1 | 2017 | 38 | 0.600 |
Why?
| Sulfonamides | 2 | 2017 | 455 | 0.550 |
Why?
| Drug Resistance, Neoplasm | 2 | 2017 | 673 | 0.510 |
Why?
| Epilepsy | 1 | 2018 | 291 | 0.500 |
Why?
| Tumor Suppressor Proteins | 3 | 2021 | 299 | 0.430 |
Why?
| Whole-Body Irradiation | 1 | 2012 | 72 | 0.430 |
Why?
| Neoplasms | 2 | 2019 | 2235 | 0.430 |
Why?
| Antineoplastic Agents | 4 | 2017 | 1990 | 0.410 |
Why?
| Ependymoma | 3 | 2019 | 174 | 0.400 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 543 | 0.400 |
Why?
| Mutation | 5 | 2021 | 3493 | 0.360 |
Why?
| Survivors | 1 | 2012 | 440 | 0.340 |
Why?
| Oncogene Proteins, Fusion | 2 | 2021 | 182 | 0.340 |
Why?
| RNA-Binding Proteins | 2 | 2021 | 392 | 0.300 |
Why?
| Cell Survival | 3 | 2019 | 1075 | 0.280 |
Why?
| Cell Line, Tumor | 6 | 2019 | 2904 | 0.280 |
Why?
| Cerebellar Neoplasms | 2 | 2018 | 135 | 0.270 |
Why?
| Medulloblastoma | 2 | 2018 | 177 | 0.260 |
Why?
| Child | 11 | 2021 | 19561 | 0.240 |
Why?
| Humans | 26 | 2021 | 122796 | 0.240 |
Why?
| Biomarkers, Tumor | 3 | 2019 | 1076 | 0.230 |
Why?
| Child, Preschool | 7 | 2021 | 9755 | 0.230 |
Why?
| STAT3 Transcription Factor | 2 | 2015 | 193 | 0.220 |
Why?
| Clinical Trials as Topic | 2 | 2019 | 985 | 0.210 |
Why?
| raf Kinases | 1 | 2021 | 12 | 0.210 |
Why?
| Protein Kinase Inhibitors | 2 | 2021 | 833 | 0.210 |
Why?
| Radiation | 1 | 2021 | 27 | 0.200 |
Why?
| Ubiquitin Thiolesterase | 1 | 2021 | 38 | 0.200 |
Why?
| Pituitary Diseases | 1 | 2020 | 23 | 0.190 |
Why?
| Histiocytosis, Langerhans-Cell | 1 | 2020 | 36 | 0.190 |
Why?
| Infant | 4 | 2019 | 8523 | 0.180 |
Why?
| Pituitary Gland | 1 | 2020 | 164 | 0.180 |
Why?
| MAP Kinase Signaling System | 1 | 2021 | 304 | 0.180 |
Why?
| N-Myc Proto-Oncogene Protein | 1 | 2019 | 7 | 0.180 |
Why?
| Neoplasms, Neuroepithelial | 1 | 2019 | 18 | 0.180 |
Why?
| Biological Assay | 2 | 2021 | 123 | 0.180 |
Why?
| Immunocompromised Host | 1 | 2021 | 205 | 0.180 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 2019 | 28 | 0.180 |
Why?
| Aminopyridines | 1 | 2019 | 86 | 0.170 |
Why?
| Benzamides | 1 | 2019 | 175 | 0.170 |
Why?
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 50 | 0.170 |
Why?
| Multigene Family | 1 | 2019 | 200 | 0.170 |
Why?
| Skull Neoplasms | 1 | 2017 | 22 | 0.160 |
Why?
| Rhabdomyoma | 1 | 2017 | 10 | 0.150 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 28 | 0.150 |
Why?
| Angiomyolipoma | 1 | 2017 | 18 | 0.150 |
Why?
| Adolescent | 7 | 2021 | 18948 | 0.150 |
Why?
| Male | 12 | 2021 | 59639 | 0.150 |
Why?
| Sarcoma, Ewing | 1 | 2017 | 66 | 0.150 |
Why?
| Heart Neoplasms | 1 | 2017 | 51 | 0.150 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 361 | 0.150 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.150 |
Why?
| Immunophenotyping | 1 | 2017 | 288 | 0.140 |
Why?
| Blotting, Western | 1 | 2019 | 1225 | 0.140 |
Why?
| Transplantation Conditioning | 1 | 2017 | 158 | 0.140 |
Why?
| Pyrimidines | 1 | 2019 | 388 | 0.140 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 75 | 0.140 |
Why?
| Immunotherapy, Adoptive | 1 | 2018 | 192 | 0.140 |
Why?
| Drug Synergism | 1 | 2017 | 346 | 0.140 |
Why?
| Feasibility Studies | 1 | 2019 | 780 | 0.140 |
Why?
| Outpatients | 1 | 2019 | 336 | 0.140 |
Why?
| Receptor, ErbB-2 | 1 | 2018 | 321 | 0.140 |
Why?
| Flow Cytometry | 1 | 2019 | 1128 | 0.140 |
Why?
| Prognosis | 3 | 2019 | 3563 | 0.130 |
Why?
| Seizures | 1 | 2018 | 360 | 0.130 |
Why?
| Signal Transduction | 2 | 2021 | 4902 | 0.130 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 563 | 0.130 |
Why?
| Cell Proliferation | 3 | 2017 | 2328 | 0.130 |
Why?
| Genetic Testing | 1 | 2017 | 400 | 0.130 |
Why?
| Apoptosis | 3 | 2019 | 2532 | 0.130 |
Why?
| Excitatory Amino Acid Agonists | 1 | 2014 | 39 | 0.120 |
Why?
| NF-kappa B | 1 | 2017 | 676 | 0.120 |
Why?
| Brain Stem | 1 | 2014 | 104 | 0.110 |
Why?
| Retrospective Studies | 4 | 2021 | 13433 | 0.110 |
Why?
| Kidney Neoplasms | 1 | 2017 | 331 | 0.110 |
Why?
| Female | 10 | 2021 | 63629 | 0.110 |
Why?
| Nuclear Proteins | 1 | 2017 | 618 | 0.110 |
Why?
| Histones | 1 | 2018 | 562 | 0.110 |
Why?
| MicroRNAs | 1 | 2019 | 661 | 0.110 |
Why?
| Treatment Outcome | 3 | 2017 | 9692 | 0.110 |
Why?
| Cohort Studies | 2 | 2021 | 5294 | 0.110 |
Why?
| Glutamic Acid | 1 | 2014 | 227 | 0.110 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2014 | 164 | 0.100 |
Why?
| Interleukin-6 | 1 | 2015 | 702 | 0.100 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 167 | 0.090 |
Why?
| Young Adult | 3 | 2021 | 11094 | 0.090 |
Why?
| Skin Neoplasms | 1 | 2017 | 841 | 0.090 |
Why?
| Hippocampus | 1 | 2014 | 747 | 0.090 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1183 | 0.080 |
Why?
| Animals | 6 | 2021 | 34133 | 0.080 |
Why?
| Cognition Disorders | 1 | 2012 | 547 | 0.080 |
Why?
| Neuropsychological Tests | 1 | 2012 | 1072 | 0.080 |
Why?
| Phenotype | 1 | 2015 | 3070 | 0.070 |
Why?
| Adult | 2 | 2019 | 32385 | 0.070 |
Why?
| Aged, 80 and over | 1 | 2018 | 6845 | 0.070 |
Why?
| Neurons | 1 | 2014 | 1345 | 0.070 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 3264 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1174 | 0.070 |
Why?
| Computer Simulation | 2 | 2021 | 945 | 0.060 |
Why?
| Lung Neoplasms | 1 | 2017 | 2216 | 0.060 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 551 | 0.060 |
Why?
| Gene Ontology | 1 | 2021 | 57 | 0.050 |
Why?
| Autophagosomes | 1 | 2021 | 21 | 0.050 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2021 | 190 | 0.050 |
Why?
| Autophagy-Related Proteins | 1 | 2021 | 48 | 0.050 |
Why?
| Neoplasm Grading | 1 | 2021 | 265 | 0.050 |
Why?
| Lysosomes | 1 | 2021 | 136 | 0.050 |
Why?
| Phosphorylation | 2 | 2015 | 1733 | 0.050 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 2019 | 28 | 0.040 |
Why?
| Viral Load | 1 | 2021 | 423 | 0.040 |
Why?
| Aged | 1 | 2018 | 20495 | 0.040 |
Why?
| Oncogenes | 1 | 2019 | 118 | 0.040 |
Why?
| Injections, Intraventricular | 1 | 2018 | 74 | 0.040 |
Why?
| Enhancer Elements, Genetic | 1 | 2019 | 162 | 0.040 |
Why?
| Macaca mulatta | 1 | 2018 | 145 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2020 | 1021 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 244 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2018 | 152 | 0.040 |
Why?
| Middle Aged | 1 | 2018 | 28563 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2019 | 383 | 0.040 |
Why?
| DNA Methylation | 1 | 2021 | 511 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2019 | 320 | 0.040 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.040 |
Why?
| Genes, myc | 1 | 2016 | 47 | 0.040 |
Why?
| Cell Cycle | 1 | 2019 | 584 | 0.040 |
Why?
| Urea | 1 | 2016 | 78 | 0.040 |
Why?
| Radiotherapy | 1 | 2017 | 187 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| Transcriptome | 1 | 2021 | 774 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 360 | 0.030 |
Why?
| Cisplatin | 1 | 2016 | 269 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 89 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 661 | 0.030 |
Why?
| Beclin-1 | 1 | 2014 | 12 | 0.030 |
Why?
| Autophagy-Related Protein 7 | 1 | 2014 | 11 | 0.030 |
Why?
| Pepstatins | 1 | 2014 | 5 | 0.030 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2014 | 17 | 0.030 |
Why?
| Sequestosome-1 Protein | 1 | 2014 | 18 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 129 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 884 | 0.030 |
Why?
| Leucine | 1 | 2014 | 117 | 0.030 |
Why?
| Pyrazoles | 1 | 2016 | 366 | 0.030 |
Why?
| Heat-Shock Proteins | 1 | 2014 | 129 | 0.030 |
Why?
| Protease Inhibitors | 1 | 2014 | 106 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2014 | 198 | 0.030 |
Why?
| Tumor Burden | 1 | 2014 | 277 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2014 | 416 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 1188 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 2079 | 0.030 |
Why?
| Doxorubicin | 1 | 2014 | 304 | 0.030 |
Why?
| Microtubule-Associated Proteins | 1 | 2014 | 187 | 0.030 |
Why?
| Mice, Nude | 1 | 2014 | 668 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 523 | 0.030 |
Why?
| RNA Interference | 1 | 2014 | 473 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 515 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 1756 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2014 | 581 | 0.030 |
Why?
| Animals, Newborn | 1 | 2014 | 825 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2014 | 421 | 0.030 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2014 | 747 | 0.030 |
Why?
| Biomarkers | 1 | 2021 | 3662 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2019 | 4768 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 2359 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2019 | 2491 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1402 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2015 | 1625 | 0.020 |
Why?
| Membrane Proteins | 1 | 2014 | 1093 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1928 | 0.020 |
Why?
| Cells, Cultured | 1 | 2014 | 4162 | 0.020 |
Why?
| Rats | 1 | 2014 | 5426 | 0.020 |
Why?
| Mice | 1 | 2014 | 15888 | 0.010 |
Why?
|
|
Mulcahy Levy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|